Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.50 |
| ▸ | FNTB | P49356 | 2/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.50 |
| ▸ | NPY4R | P50391 | 13/20 | 0.47 |
| ▸ | NPY1R | P25929 | 9/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.47 |
| ▸ | NPY2R | P49146 | 5/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | LAP3 | P28838 | 2/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570265 | 1.00 | FNTA (0.50) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL7435202 | 0.91 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL21570230 | 0.91 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7435218 | 0.91 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7435439 | 0.90 | LAP3 (0.53) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL21570268 | 0.90 | LAP3 (0.53) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL29674598 | 0.90 | LAP3 (0.53) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL7435448 | 0.90 | LAP3 (0.53) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL7445350 | 0.89 | LAP3 (0.52) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| Hydrochloric Acid SCHEMBL7445342 | 0.89 | LAP3 (0.52) | FNTAFNTBPGGT1BNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FNTA 762/4885FNTB 1738/4885PGGT1B 559/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | FNTA 762/4885FNTB 1738/4885PGGT1B 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.